After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate

  • Biogen Inc BIIB and Ionis Pharmaceuticals Inc IONS have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild Alzheimer's disease.
  • The trial met its primary objective of safety and tolerability. It demonstrated dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period.
  • The candidate exhibited a mean percentage reduction of 30%, 40%, and 49% in the low, medium, and high dose groups treated every four weeks, respectively, and 42% in the group treated every 12 weeks. 
  • Total-tau in the CSF continued to decline 16 weeks post-last dose in patients treated with BIIB080 in the high dose four-week and 12-week dose groups, showing a 55% and 49% mean reduction from baseline, respectively. 
  • CSF was not collected 16 weeks post-last dose in the low and medium four-week dose groups. 
  • There were similar dose-dependent decreases in the levels of phosphorylated tau. 
  • All participants (n=46) completed the Multiple Ascending Dose (MAD) period, and 43 participants completed the Post-Treatment (PT) period (3 participants voluntarily withdrew). 
  • Price Action: BIIB shares closed at $331.93, and IONS stock closed at $37.42 on Monday.

Posted In: AduhelmAlzheimer's diseaseBriefsBiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.